Comera Life Sciences Holdings, Inc.

Overview

• IndustryPharmaceutical Preparations¹
• HeadquartersWoburn, Massachusetts¹
• Incorporated inDE²
• Business address12 Gill Street, Suite 4650, Woburn, Ma 01801²
• Filer category, Emerging growth company²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

Comera Life Sciences Holdings, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Comera Life Sciences Holdings, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Leadership

Who has led Comera Life Sciences Holdings, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief financial officerMichael Gerard Campbell Jun 17, 2022 to Nov 28, 2023⁶
• Chief operating officerNeal Muni Aug 11, 2022 to Oct 16, 2023⁷

Timeline

1. Feb 26, 20248-K Other events²¹
2. Jan 30, 20248-K Debt or obligation accelerated; Exit or restructuring costs; Executive or director change²²
3. Jan 4, 20248-K Other events²³
4. Jan 3, 20248-K Regulation FD disclosure²⁴
5. Dec 29, 20238-K Entered a material agreement; New debt or obligation; Unregistered sale of shares²⁵
6. Dec 6, 20238-K Other events²⁶
7. Nov 16, 20238-K Listing notice or transfer²⁷
8. Nov 9, 20238-K Results of operations²⁸
9. Nov 3, 20238-K Listing notice or transfer²⁹
10. Oct 6, 20238-K Executive or director change³⁰
11. Oct 2, 20238-K Regulation FD disclosure³¹
12. Sep 13, 20238-K Regulation FD disclosure³²

Calendar

When it reported results

1. Nov 9, 2023Reported quarterly or annual results²⁸
2. Aug 10, 2023Reported quarterly or annual results³³
3. May 12, 2023Reported quarterly or annual results³⁴
4. Mar 16, 2023Reported quarterly or annual results³⁵
5. Nov 10, 2022Reported quarterly or annual results³⁶
6. Aug 15, 2022Reported quarterly or annual results³⁷

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

295 filings to the SEC since October 2021: 1 annual reports, 5 quarterly reports, 31 major events, 109 insider forms, 16 large holders, 4 private raises, 129 other. The latest 20:

1. Feb 27, 2024EFFECT EDGAR
2. Feb 27, 2024EFFECT EDGAR
3. Feb 27, 2024EFFECT EDGAR
4. Feb 27, 2024EFFECT EDGAR
5. Feb 26, 2024S-8 POS EDGAR
6. Feb 26, 2024S-8 POS EDGAR
7. Feb 26, 2024S-8 POS EDGAR
8. Feb 26, 2024POS AM EDGAR
9. Feb 26, 2024POS AM EDGAR
10. Feb 26, 2024POS AM EDGAR
11. Feb 26, 2024POS AM EDGAR
12. Feb 26, 20248-K EDGAR
13. Feb 2, 20244 OWNERSHIP DOCUMENT EDGAR
14. Feb 2, 20243 OWNERSHIP DOCUMENT EDGAR
15. Jan 30, 2024424B3 EDGAR
16. Jan 30, 2024424B3 EDGAR
17. Jan 30, 2024424B3 EDGAR
18. Jan 30, 20248-K EDGAR
19. Jan 11, 20244 OWNERSHIP DOCUMENT EDGAR
20. Jan 11, 20243 OWNERSHIP DOCUMENT EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

25 open-market trades by officers, directors and large owners since October 2021: 25 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Charles CheringtonSC 13D, 5 filings Sep 13, 2022 to Jan 8, 2024³⁸
• IAF, LLCSC 13G/A, 2 filings Aug 10, 2023 to Sep 6, 2023³⁹
• Nicholas Jason SingerSC 13G, 1 filing Aug 24, 2023⁴⁰
• OTR Acquisition Sponsor LLCSC 13G, 1 filing Aug 16, 2023⁴¹
• David SoaneSC 13D/A, 3 filings Oct 28, 2022 to Aug 4, 2023⁴²
• Freebird Partners LPSC 13G, 1 filing Jan 10, 2023⁴³
• Michael RabinowitzSC 13G/A, 2 filings Jun 3, 2022 to Jun 16, 2022⁴⁴
• Phoenix Venture Partners LPSC 13G, 1 filing May 31, 2022⁴⁵

Money raised

Private offerings the company reported to the SEC on Form D.

1. Dec 29, 2023Raised $1.5 million in a private offering of debt Form D: 12 investors so far Form D
2. Jul 31, 2023Raised $2.2 million in a private offering of equity Form D: $4.1 million offered in all Form D
3. Jul 31, 2023Raised $238,336 in a private offering of equity Form D: 1 investor so far Form D
4. Jan 4, 2023Raised $3.6 million in a private offering of equity Form D: 14 investors so far Form D

SEC filer profile

How Comera Life Sciences Holdings, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARComera Life Sciences Holdings, Inc.¹
• CIK0001907685
• Employer ID (EIN)87-4706968¹
• Filer status<br>emerging growth company¹
• Incorporated inDelaware¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address12 Gill Street, Suite 4650, Woburn, MA 01801¹
• Phone(617)871-2101¹
• Shares outstanding30,737,796 as of Nov 8, 2023⁵
• Public float$22.6M as of Jun 30, 2022³
• On EDGAR sinceFeb 3, 2022¹
• Filings298 in all: 4 (69), 424B3 (64), 8-K (31), 3 (24), EFFECT (12), CORRESP (9), 425 (7), 5 (7)¹
  All 35 form types

  POS AM (7), UPLOAD (7), 4/A (6), SC 13G (6), 10-Q (5), SC 13D/A (5), D (4), 3/A (3), S-1 (3), S-1/A (3), S-4/A (3), S-8 (3), S-8 POS (3), SC 13D (3), SC 13G/A (2), 10-K (1), 25-NSE (1), 8-A12B (1), ARS (1), CERT (1), DEF 14A (1), DEL AM (1), DRS (1), DRSLTR (1), PRE 14A (1), S-3 (1), S-4 (1)

• Latest filingsAnnual report (10-K) Mar 17, 2023
  Quarterly report (10-Q) Nov 9, 2023
  Proxy statement (DEF 14A) Aug 11, 2023
  Latest 8-K (8-K) Feb 26, 2024